198281-55-9

Basic information

• Product Name: 3-(4-METHYL-PIPERAZIN-1-YLMETHYL)-ANILINE
• Synonyms: 3-(4-METHYL-PIPERAZIN-1-YLMETHYL)-PHENYLAMINE;3-(4-METHYL-PIPERAZIN-1-YLMETHYL)-ANILINE;TIMTEC-BB SBB007471;Benzenamine, 3-[(4-methyl-1-piperazinyl)methyl]-
• CAS NO: 198281-55-9
• Molecular Formula: C₁₂H₁₉N₃
• Molecular Weight: 205.3
• Mol File: 198281-55-9.mol
• Article Data: 10

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-(4-METHYL-PIPERAZIN-1-YLMETHYL)-ANILINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(4-METHYL-PIPERAZIN-1-YLMETHYL)-ANILINE(198281-55-9)
• EPA Substance Registry System: 3-(4-METHYL-PIPERAZIN-1-YLMETHYL)-ANILINE(198281-55-9)

Safety Data

• Hazard Codes: Xi
• Statements: 36
• Safety Statements: 26
• Hazardous Substances Data: 198281-55-9(Hazardous Substances Data)

Usage

Description

3-(4-METHYL-PIPERAZIN-1-YLMETHYL)-ANILINE is an organic compound that serves as a key intermediate in the synthesis of various chemical compounds, particularly those with potential pharmaceutical applications. It is characterized by its unique molecular structure, which features a piperazine ring and an aniline group, allowing it to form important bonds and interactions with other molecules.

Uses

Used in Pharmaceutical Industry:
3-(4-METHYL-PIPERAZIN-1-YLMETHYL)-ANILINE is used as a chemical intermediate for the preparation of pyrido[3,4-d]pyrimidin-4-ol derivatives. These derivatives have been identified as histone demethylase inhibitors, which play a crucial role in the regulation of gene expression and have potential applications in the treatment of various diseases, including cancer.
Used in the Synthesis of Histone Demethylase Inhibitors:
3-(4-METHYL-PIPERAZIN-1-YLMETHYL)-ANILINE is used as a building block in the development of novel histone demethylase inhibitors. These inhibitors can modulate the activity of histone demethylases, which are enzymes that remove methyl groups from histone proteins, thereby affecting gene expression. By targeting these enzymes, histone demethylase inhibitors may offer therapeutic benefits in the treatment of diseases with aberrant epigenetic regulation, such as cancer.

Upstream product

• 3958-57-4 1-bromomethyl-3-nitrobenzene 
• 99-61-6 3-nitro-benzaldehyde 
• 619-23-8 3-Nitrobenzyl chloride 
• 1015484-22-6 1-methyl-4-((trifluoro-λ⁴-boranyl)methyl)piperazine potassium 
• 108-42-9 3-chloro-aniline 
• 198281-54-8 1-methyl-4-(3-nitro-benzyl)-piperazine 
• 109-01-3 1-methyl-piperazine 

Downstream Products

• 1350443-59-2 4-(4-methylpiperazin-1-ylmethyl)-N-[3-(4-methylpiperazin-1-ylmethyl)phenyl]benzamide 
• 1429617-80-0 C₂₈H₂₈N₆O 
• 1371209-21-0 C₂₀H₂₄N₄O₃ 
• 943189-22-8 N-methyl-N'-[3-(4-methylpiperazin-1-ylmethyl)phenyl]pyrimidine-4,6-diamine 
• 503183-26-4 4-{[3-((4-methylpiperazin-1-yl)methyl)phenyl]hydrazono}-4H-pyrazole-3,5-diamine 

Relevant articles and documents

Methylpyrazole derivatives as RET inhibitor

The invention relates to a methylpyrazole derivative as an RET inhibitor, in particular to a compound as shown in a formula (I), a stereoisomer and pharmaceutically acceptable salt thereof, a preparation method and a pharmaceutical composition thereof. The compound of the formula (I) can be used for preventing or treating diseases mediated by abnormal RET activity.

2, 4 -DIAMINOPYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS

The present invention relates to novel pyrimide derivatives of formula (I): that are useful as kinase inhibitors. More particularly, the present invention relates to novel pyrimidine compounds, methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment of proliferative disorders.

Synthesis of new amides of the N-methylpiperazine series

New carboxylic acid amides containing an N-methylpiperazine fragment were synthesized by reactions of 1-methylpiperazine or 3- and 4-(4-methylpiperazin-1- ylmethyl)aniline with 4-chlorobenzoyl chloride and of 4-methyl-3-nitroaniline with 4-(4-methylpiperazin-1-ylmethyl)benzoyl chloride or benzotriazol-1-yl 4-(4-methylpiperazin-1-ylmethyl)benzoate. 4-Chloro-N-[4-(4-methylpiperazin-1- ylmethyl)phenyl]benzamide reacted with imidazole, quinolin-5-amine, and 2-methylquinolin-5-amine to give substituted 4-amino-N-[4-(4- methylpiperazin-1-ylmethyl)phenyl]benzamides. 4-Methyl-3-nitrophenyl-4- methylpiperazin-1-yl-substituted benzamides were reduced with hydrazine hydrate over Raney nickel to obtain N-(3-amino-4-methylphenyl)-4- (4-methylpiperazin-1- ylmethyl)benzamide as key intermediate in the synthesis of antileukemic agent imatinib and its isomer with alternative position of the amide group, 4-[(3-amino-4-methylphenylamino)methyl]phenyl- (4-methylpiperazin-1-yl)} methanone. Pleiades Publishing, Ltd., 2011.